用于癌症个性化精准医疗的表观遗传体外诊断测试
Epigenetic IVD Tests for Personalized Precision Medicine in Cancer.
作者信息
Beltrán-García Jesús, Osca-Verdegal Rebeca, Mena-Mollá Salvador, García-Giménez José Luis
机构信息
Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain.
INCLIVA Biomedical Research Institute, Valencia, Spain.
出版信息
Front Genet. 2019 Jun 28;10:621. doi: 10.3389/fgene.2019.00621. eCollection 2019.
Abstract
Epigenetic alterations play a key role in the initiation and progression of cancer. Therefore, it is possible to use epigenetic marks as biomarkers for predictive and precision medicine in cancer. Precision medicine is poised to impact clinical practice, patients, and healthcare systems. The objective of this review is to provide an overview of the epigenetic testing landscape in cancer by examining commercially available epigenetic-based diagnostic tests for colon, breast, cervical, glioblastoma, lung cancers, and for cancers of unknown origin. We compile current commercial epigenetic tests based on epigenetic biomarkers (i.e., DNA methylation, miRNAs, and histones) that can actually be implemented into clinical practice.
摘要
表观遗传改变在癌症的发生和发展中起着关键作用。因此，有可能将表观遗传标记用作癌症预测和精准医学的生物标志物。精准医学有望对临床实践、患者和医疗保健系统产生影响。本综述的目的是通过研究用于结肠癌、乳腺癌、宫颈癌、胶质母细胞瘤、肺癌以及原发灶不明癌症的基于表观遗传的商用诊断测试，概述癌症表观遗传检测的现状。我们汇总了目前基于表观遗传生物标志物（即DNA甲基化、微小RNA和组蛋白）且可实际应用于临床实践的商用表观遗传测试。
相似文献
1
Epigenetic IVD Tests for Personalized Precision Medicine in Cancer.用于癌症个性化精准医疗的表观遗传体外诊断测试
Front Genet. 2019 Jun 28;10:621. doi: 10.3389/fgene.2019.00621. eCollection 2019.
2
Early Epigenetic Markers for Precision Medicine.精准医学的早期表观遗传标志物。
Methods Mol Biol. 2018;1856:3-17. doi: 10.1007/978-1-4939-8751-1_1.
3
Epigenetic primer for diagnostic applications: a window into personalized medicine.诊断应用的表观遗传学入门：通往个性化医疗的一扇窗。
Per Med. 2014 May;11(3):323-337. doi: 10.2217/pme.14.21.
4
Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine.循环游离核酸作为精准医学中的表观遗传生物标志物
Front Genet. 2020 Aug 11;11:844. doi: 10.3389/fgene.2020.00844. eCollection 2020.
5
Epigenetic alternations and cancer chemotherapy response.表观遗传改变与癌症化疗反应。
Cancer Chemother Pharmacol. 2016 Apr;77(4):673-84. doi: 10.1007/s00280-015-2951-0. Epub 2015 Dec 26.
6
Biomarkers for personalized oncology: recent advances and future challenges.用于肿瘤个体化医学的生物标志物：最新进展与未来挑战。
Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30.
7
HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer.HLJ1（DNAJB4）基因是乳腺癌中一种新的生物标志物候选基因。
OMICS. 2017 May;21(5):257-265. doi: 10.1089/omi.2017.0016.
8
Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.基于循环游离DNA的表观遗传学检测可检测早期乳腺癌。
Breast Cancer Res. 2016 Dec 19;18(1):129. doi: 10.1186/s13058-016-0788-z.
9
Liquid biopsy: a step forward towards precision medicine in urologic malignancies.液体活检：朝着泌尿生殖系统恶性肿瘤精准医学迈进的一步。
Mol Cancer. 2017 Apr 14;16(1):80. doi: 10.1186/s12943-017-0644-5.
10
Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies.用于高发性恶性肿瘤液体活检的癌症表观遗传生物标志物
Cancers (Basel). 2021 Jun 16;13(12):3016. doi: 10.3390/cancers13123016.
引用本文的文献
1
A review of the use of tumour DNA methylation for breast cancer subtyping and prediction of outcomes.肿瘤DNA甲基化在乳腺癌亚型分类及预后预测中的应用综述。
Clin Epigenetics. 2025 Jul 2;17(1):109. doi: 10.1186/s13148-025-01922-z.
2
Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer.基于液体活检的DNA甲基化生物标志物在乳腺癌精准医学中的应用
Expert Rev Mol Med. 2025 Jun 17;27:e20. doi: 10.1017/erm.2025.10008.
3
Circulating cell-free DNA methylation as biomarker for lung cancer detection: a systematic review and meta-analysis of diagnostic studies.循环游离DNA甲基化作为肺癌检测的生物标志物：诊断性研究的系统评价和荟萃分析
Syst Rev. 2025 Jun 2;14(1):120. doi: 10.1186/s13643-025-02860-w.
4
Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer.三阴性乳腺癌与非三阴性乳腺癌的甲基化模式分子特征分析
Sci Rep. 2025 Feb 26;15(1):6894. doi: 10.1038/s41598-025-90150-9.
5
Harnessing ferroptosis for precision oncology: challenges and prospects.利用铁死亡实现精准肿瘤学：挑战与前景
BMC Biol. 2025 Feb 24;23(1):57. doi: 10.1186/s12915-025-02154-6.
6
DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications.前列腺癌中的DNA甲基化：临床意义与潜在应用
Cancer Med. 2025 Jan;14(1):e70528. doi: 10.1002/cam4.70528.
7
Climbing the longevity pyramid: overview of evidence-driven healthcare prevention strategies for human longevity.攀登长寿金字塔：人类长寿的循证医疗预防策略概述
Front Aging. 2024 Nov 26;5:1495029. doi: 10.3389/fragi.2024.1495029. eCollection 2024.
8
Molecular and modular intricacies of precision oncology.精准肿瘤学的分子和模块复杂性。
Front Immunol. 2024 Oct 23;15:1476494. doi: 10.3389/fimmu.2024.1476494. eCollection 2024.
9
Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review.基于血液DNA甲基化检测的结直肠癌早期诊断研究进展：系统更新综述
Gastroenterol Hepatol Bed Bench. 2024;17(3):225-240. doi: 10.22037/ghfbb.v17i3.2978.
10
MicroRNAs in Genitourinary Malignancies: An Exciting Frontier of Cancer Diagnostics and Therapeutics.泌尿生殖系统恶性肿瘤中的 microRNAs：癌症诊断与治疗的激动人心新领域。
Int J Mol Sci. 2024 Aug 31;25(17):9499. doi: 10.3390/ijms25179499.
本文引用的文献
1
Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA.基于粪便 DNA 中甲基化 syndecan-2（SDC2）的存在进行结直肠癌的早期检测。
Clin Epigenetics. 2019 Mar 15;11(1):51. doi: 10.1186/s13148-019-0642-0.
2
ZNF582 methylation as a potential biomarker to predict cervical intraepithelial neoplasia type III/worse: A meta-analysis of related studies in Chinese population.锌指蛋白582甲基化作为预测宫颈上皮内瘤变III级及以上病变的潜在生物标志物：中国人群相关研究的荟萃分析
Medicine (Baltimore). 2019 Feb;98(6):e14297. doi: 10.1097/MD.0000000000014297.
3
Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer.临床性能的分析验证的测定与微阵列技术来评估 PITX2 DNA 甲基化在乳腺癌。
Sci Rep. 2018 Nov 15;8(1):16861. doi: 10.1038/s41598-018-34919-1.
4
The quantitative profiling of blood mSEPT9 determines the detection performance on colorectal tumors.血液 mSEPT9 的定量分析可确定结直肠肿瘤的检测性能。
Epigenomics. 2018 Dec;10(12):1569-1583. doi: 10.2217/epi-2017-0154. Epub 2018 Nov 14.
5
Universal cancer screening: revolutionary, rational, and realizable.通用癌症筛查：具有革命性、合理性且切实可行。
NPJ Precis Oncol. 2018 Oct 29;2:23. doi: 10.1038/s41698-018-0066-x. eCollection 2018.
6
Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas.基因启动子甲基化状态——两种焦磷酸测序试剂盒和三种甲基化特异性PCR方法在胶质母细胞瘤预测能力方面的评估
Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):437-446. doi: 10.21873/cgp.20102.
7
Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.乳腺癌靶向治疗的演进：精准医学的起源
Am Soc Clin Oncol Educ Book. 2018 May 23;38:78-86. doi: 10.1200/EDBK_201037.
8
The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA.结直肠癌的病理特征决定了血液中循环肿瘤DNA（ctDNA）的检测性能。
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818791794. doi: 10.1177/1533033818791794.
9
Pyrosequencing Analysis of Promoter Methylation in Meningioma.脑膜瘤启动子甲基化的焦磷酸测序分析
Cancer Genomics Proteomics. 2018 Sep-Oct;15(5):379-385. doi: 10.21873/cgp.20096.
10
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in Wild-Type Metastatic Colorectal Cancer.miR-31-3p 表达验证预测野生型转移性结直肠癌一线使用西妥昔单抗的疗效。
Clin Cancer Res. 2019 Jan 1;25(1):134-141. doi: 10.1158/1078-0432.CCR-18-1324. Epub 2018 Aug 14.
Zotero 插件